

1 **Pregnancy and birth outcomes after SARS-CoV-2 vaccination** 2 **in pregnancy**

3
4 Regan N. Theiler, MD, PhD*¹, Myra Wick, MD, PhD¹, Ramila Mehta³, Amy Weaver, MS³,
5 Abinash Virk, MD², Melanie Swift, MD⁵

6
7 ¹ Mayo Clinic Department of Obstetrics and Gynecology, Division of Obstetrics

8 ² Mayo Clinic Department of Medicine, Division of Infectious Disease

9 ³ Mayo Clinic Department of Quantitative Health Sciences

10 ⁵ Mayo Clinic Division of Preventive, Occupational, and Aerospace Medicine

11
12 *Corresponding author:

13
14 200 First St SE
15 Department of Obstetrics and Gynecology
16 Mayo Clinic
17 Rochester, MN 55905
18 Theiler.Regan@Mayo.edu

19
20
21 **Disclosures:**

22
23 Dr. Theiler has a know-how license and research funding from HeraMED
24 Dr. Swift has funding from Pfizer via Duke University for the HERO Together vaccine safety
25 registry.
26 Dr. Virk reports being an inventor for Mayo Clinic Travel App interaction with Smart Medical Kit
27 and Medical Kit for Pilgrims.
28 The other authors have declared no conflicts of interest

29
30
31
32 **Acknowledgments:**

33
34 This work was funded in part by grant FP00085005-A1-03-S14 from the U.S. National Center for
35 Translational Sciences. The funder did not participate in the study design, data collection, data
36 analysis, or writing for publication.

37
38
39
40
41
42

43 **ABSTRACT**

44

45 **Background:** SARS-CoV-2 infection during pregnancy is associated with significant maternal
46 morbidity and increased rates of preterm birth. For this reason, COVID-19 vaccine
47 administration in pregnancy has been endorsed by multiple professional societies including
48 ACOG and SMFM despite exclusion of pregnant women from initial clinical trials of vaccine
49 safety and efficacy. However, to date little data exists regarding outcomes after COVID-19
50 vaccination of pregnant patients.

51 **Study Design:** A comprehensive vaccine registry was combined with a delivery database for an
52 integrated healthcare system to create a delivery cohort including vaccinated patients. Maternal
53 sociodemographic data were examined univariately for factors associated with COVID-19
54 vaccination. Pregnancy and birth outcomes were analyzed, including a composite measure of
55 maternal and neonatal pregnancy complications, the Adverse Outcome Index.

56 **Results:** Of 2002 patients in the delivery cohort, 140 (7.0%) received a COVID-19 vaccination
57 during pregnancy and 212 (10.6%) experienced a COVID-19 infection during pregnancy. The
58 median gestational age at first vaccination was 32 weeks (range 13 6/7-40 4/7), and patients
59 vaccinated during pregnancy were less likely than unvaccinated patients to experience COVID-
60 19 infection prior to delivery (1.4% (2/140) vs. 11.3% (210/1862)) $P<0.001$ No maternal COVID-
61 19 infections occurred after vaccination during pregnancy.

62 Factors significantly associated with increased likelihood of vaccination included older age,
63 higher level of maternal education, lower pre-pregnancy BMI, and use of infertility treatment for
64 the current pregnancy. Tobacco or other substance use, Hispanic ethnicity, and higher gravidity
65 were associated with a lower likelihood of vaccination. No significant difference in the composite
66 adverse outcome (5.0% (7/140) vs. 4.9% (91/1862) $P=0.95$) or other maternal or neonatal

67 complications, including thromboembolic events and preterm birth, was observed in vaccinated
68 mothers compared to unvaccinated patients.

69 **Conclusions:** Vaccinated pregnant women in this birth cohort were less likely to experience
70 COVID-19 infection compared to unvaccinated pregnant patients, and COVID-19 vaccination
71 during pregnancy was not associated with increased pregnancy or delivery complications.
72 Significant sociodemographic disparities in vaccine uptake and/or access were observed among
73 pregnant patients, and future efforts should focus on outreach to low-uptake populations.

74 **Introduction**

75 In late 2020, the United States Food and Drug Administration (FDA) approved two mRNA
76 vaccines, manufactured by Pfizer-BioNTech (BNT162b2) vaccine (Pfizer, Inc; Philadelphia,
77 Pennsylvania) and Moderna (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge,
78 Massachusetts), for emergency use to prevent COVID-19 illness. Both vaccines were studied in
79 large numbers of subjects during phase 3 randomized controlled trials, and both were shown to
80 be highly effective at preventing COVID-19 infection in non-pregnant participants.^{1, 2} Because
81 none of the trials undertaken to gain FDA approval included pregnant or lactating women, use of
82 the vaccines during pregnancy and lactation has been controversial.³ During phase 1A of the
83 vaccine rollout in the U.S., healthcare workers were the first population with access to
84 vaccination, and thus many pregnant healthcare workers have received the vaccine. During
85 phase 1B, teachers and other essential workers were vaccinated, adding to the population of
86 reproductive age who were eligible for vaccination. Starting in December 2020,
87 recommendations from the American College of Obstetricians and Gynecologists (ACOG), the
88 Society for Maternal-Fetal Medicine (SMFM), and the World Health Organization (WHO)
89 endorsed availability of COVID-19 vaccination for pregnant women using a shared decision-
90 making model with healthcare providers^{3, 4}.

91 COVID-19 disease during pregnancy is known to have severe manifestations in pregnant
92 women compared to non-pregnant controls, with increased risk for maternal hospitalization, ICU
93 admission, invasive ventilation, and death⁵⁻⁷. Because of the known increased maternal risk of
94 adverse outcomes with COVID-19 infection and the lack of theoretical or proven harm from the
95 available vaccines, many patients have opted for vaccination despite limited safety and efficacy
96 data for the vaccines in pregnant patients. The vaccines are thought to be effective when
97 administered during pregnancy, as antibody production occurs rapidly after administration.
98 However, immune alterations that occur in pregnancy may theoretically decrease the vigor of

99 cell-mediated immune responses to infection.^{2,8} Neutralizing antibody response is highly
100 reassuring and suggests robust efficacy during pregnancy with possible benefit to the neonate.
101 Recently published COVID-19 vaccine surveillance data from the Centers for Disease Control
102 and Prevention's (CDC) voluntary V-SAFE registry including 3958 subjects vaccinated during
103 pregnancy suggests that pregnant women do not have increased rates of adverse vaccine
104 reactions compared to control patients, and that patients do not report increases in adverse
105 pregnancy outcomes compared to non-pregnant women⁹. The V-SAFE data, however, are
106 limited to patient-reported reactions and pregnancy events and subject to selection bias, and
107 lack of validated primary data supporting conclusions. For this reason, vaccine efficacy should
108 be demonstrated in pregnancy using infectious outcomes as well. Adding to the available data,
109 we present pregnancy outcomes from a Mayo Clinic Health System delivery cohort delivering
110 during the first months of vaccine availability.

111

112 **Methods**

113 A comprehensive vaccine registry was created, capturing COVID-19 vaccine administrations,
114 manufacturer, and patient identifying information from Mayo Clinic vaccination sites as well as
115 other sites across the states of Minnesota and Wisconsin. The vaccination registry was then
116 linked to the Mayo Clinic delivery registry, which contains detailed maternal and neonatal
117 outcomes from all births within the Mayo Clinic Health System. The delivery registry data is
118 derived directly from elements in the electronic medical record and all fields have been validated
119 manually during development. Creation of the registries and subsequent analysis was
120 performed in accordance with human subjects regulations under approval by the Mayo Clinic
121 Institutional Review Board.

122 Criteria for study inclusion included all patients age 16-55 years old with a delivery event
123 between December 10, 2020, and April 19, 2021 at a Mayo Clinic hospital. Minnesota patients
124 who opted out of use of their medical records for research were excluded from the study if their
125 delivery occurred in Minnesota. COVID infection during pregnancy was defined as a positive
126 SARS-CoV-2 RT-PCR test documented in the medical record between the dates of conception
127 and delivery, and was stratified by first trimester (2-13 6/7 weeks gestation), second trimester
128 (14 0/7- 27 6/7 weeks gestation) and third trimester (≥ 28 weeks gestation) infection.

129 All COVID infections regardless of temporal relationship to vaccine are included in Table X. For
130 purposes of assessing vaccine side effects and pregnancy outcomes, vaccinated individuals are
131 defined as those receiving any dose of vaccine during pregnancy. For purposes of assessing
132 vaccine effectiveness, fully vaccinated was defined as >14 days after the final dose of vaccine.

133 The composite outcome, the adverse outcome index (AOI) was calculated as a composite of
134 any of the following events during the delivery hospitalization: maternal death, uterine rupture,
135 unplanned maternal ICU admission, return to the operating room within 72 hours of delivery,
136 postpartum hemorrhage with blood transfusion, third or fourth degree laceration, intrapartum
137 fetal or unexpected neonatal death (within 72hrs), hypoxic ischemic encephalopathy, five minute
138 Apgar <7 , admission to the NICU with birthweight $>2500g$, or neonatal birth trauma. All
139 qualifying events were verified by chart review. The AOI for a group of patients was calculated
140 as the number of patients with one or more identified adverse events divided by the total
141 number of deliveries, multiplied by 100. A woman with multiple gestations was counted as a
142 single delivery. A modified AOI was also calculated by not considering third- and fourth-degree
143 perineal laceration as an adverse event. Additional outcomes measured included
144 thromboembolism or stroke within 4 weeks before or after delivery, gestational hypertensive
145 disorders diagnosed up to 72 hours after delivery, low and very low birth weight, preterm birth ($<$
146 37 weeks gestation), length of postpartum maternal stay after delivery, and stillbirth.

147 The primary outcome in this study was AOI. The AOI was 4.9% within the Mayo Clinic Health
148 System for calendar year 2019. This study was designed with 80% power, using a two-sided
149 chi-square test with a type I error rate of 0.05, to detect a difference in AOI of 4.9% vs. at least
150 11.5% between those without versus with a COVID-19 vaccine during pregnancy, based on
151 1862 and 140 patients in the two groups.

152 Data management and statistical analysis was performed using SAS version 9.4 (SAS institute,
153 Cary, NC, USA). Comparisons between groups were evaluated using the chi-square test or
154 Fisher's exact test for non-ordered categorical variables, the Wilcoxon rank sum test for ordinal
155 variables, and the two-sample t-test for continuous variables. A 95% confidence interval (CI) for
156 the difference in the AOI between two groups was calculated based on exact methods for a
157 binomial parameter. All calculated p-values were two-sided and p-values less than 0.05 were
158 considered statistically significant.

159

160 **Results**

161 Of 2002 total patients, 140 received at least one dose of a COVID-19 vaccine prior to delivery,
162 and 200 experienced a COVID-19 infection during pregnancy. Among the vaccinated patients,
163 one received the Janssen COVID-19 (Ad.26.COV2.S) vaccine (Janssen Biotech, Inc, a Janssen
164 Pharmaceutical company, Johnson & Johnson; New Brunswick, New Jersey), 12 received the
165 Moderna vaccine, and 127 received the Pfizer-BioNTech vaccine (**Table 1**). The median
166 estimated gestational age (EGA) at initiation of the of the vaccination series was 32 (range 13
167 6/7-40 4/7) weeks gestation, and patients vaccinated during pregnancy were less likely than
168 unvaccinated patients to experience COVID-19 infection (1.4% vs. 4.5%, $P<0.01$) prior to
169 delivery. Completed vaccination was documented at a median EGA of 35 2/7 weeks (range 17
170 1/7-44 1/7), with 73.6% of patients completing vaccination prior to delivery.

171 Sociodemographic factors (**Table 1**) positively associated ($p < 0.05$) with maternal vaccination
172 included older maternal age at delivery, with a median of 32 (range 20-40) vs. 30 (range 16-48)
173 years of age, $P < 0.0001$). Vaccinated patients were also more educated, P trend < 0.0001 , and a
174 history of infertility treatment was also noted more frequently among vaccinated patients, with
175 6/131 (4.3%) vs. 14/1862 (0.8%) having a history of infertility therapy, ($P = 0.0018$). Factors
176 negatively associated ($p < 0.05$) with vaccination included Hispanic ethnicity (6/140 or vs.
177 173/1825, $P = .0323$), current smoking (0/140 vs. 196/1862, $P < 0.0001$), current illicit drug use
178 (0/140 vs. 56/1862, $P = 0.0301$), higher gravidity, and higher pre-pregnancy body mass index (P
179 trend = 0.0036). Race and rates of comorbid conditions including pre-gestational diabetes,
180 chronic hypertension, and asthma were not significantly associated with vaccination status.

181 Patients vaccinated during pregnancy were less likely than unvaccinated patients to experience
182 COVID-19 infection prior to delivery (1.4% (2/140) vs. 11.3% (210/1861)), $P = < 0.001$, with the
183 two infections occurring in the vaccinated group prior to vaccine administration. In the
184 unvaccinated group, COVID-19 infections occurred during each trimester of pregnancy, with 26
185 infections in the first trimester, 84 during the second trimester, and 100 in the third trimester
186 (**Table 2**). The composite pregnancy outcome, AOI, did not differ by maternal vaccination
187 status, with rates of 5.0% (7/140) vs. 4.9% (91/1862) in the vaccinated and unvaccinated groups
188 (95% CI for difference in proportions, -3.6% to 3.6%). No maternal or early neonatal deaths
189 occurred in the cohort. Mode of delivery, gestational age at delivery, neonatal birth weight,
190 thromboembolic events, and rates of gestational hypertensive disorders also did not significantly
191 differ between groups. Additional comparison between COVID-19 infected, non-vaccinated
192 patients ($n = 210$) and vaccinated patients without a history of COVID-19 infection ($n = 138$) did
193 not show any difference among the pregnancy outcomes examined in the cohort, but the study
194 was not sufficiently powered to detect a difference in these outcomes (**Appendix Table A2**).
195 Among the unvaccinated patients, pregnancy and birth outcomes did not significantly differ

196 between those with (n=210) versus without (n=1652) a COVID-19 infection during pregnancy
197 **(Appendix Table A2).**

198

199

200 **Discussion**

201 While COVID-19 infection in pregnancy has been associated with adverse maternal and
202 neonatal outcomes in multiple studies, outcomes following COVID-19 vaccination during
203 pregnancy remain largely unknown. The current cohort adds evidence of vaccine safety and
204 efficacy after administration to pregnant women during the third trimester. Given the absence of
205 infection in any vaccinated patients after the first dose administration (incidence rate ratio of
206 zero and vaccine efficacy of one) with a short observation period, our ability to estimate vaccine
207 efficacy is limited for this cohort. No patterns of adverse maternal or neonatal outcomes were
208 observed in this cohort of patients who were vaccinated under the FDA emergency use
209 authorizations, and fewer vaccinated women experienced COVID-19 infection during the
210 pregnancy. The current study largely represents outcomes after third trimester vaccination, but
211 patients who received the vaccine during the late first through second trimesters and delivered
212 preterm are represented in this data set as well. The absence of an increase in preterm births in
213 the cohort thus suggests that vaccination is unlikely to increase preterm birth rates, but analysis
214 of outcomes from currently ongoing pregnancies will be needed to confirm this finding.

215 This study reveals some sociodemographic factors associated with vaccine access and/or
216 uptake in the pregnant population. Vaccination eligibility during the timeframe analyzed was
217 limited to healthcare workers, the elderly, and teachers or other essential workers. For this
218 reason, we cannot discern whether sociodemographic differences in vaccination status are due
219 to vaccine hesitancy or eligibility for vaccination, but we do observe socioeconomic disparity

220 between those who received vaccination during gestation and those who did not. Outreach to
221 the under-represented populations of pregnant patients should be a focus of future education
222 and vaccination efforts.

223 Strengths of this study include the inclusion of comprehensive population-level vaccine registry
224 data in combination with a validated, all-inclusive delivery database including births at multiple
225 community and teaching hospitals across two states. As the data were extracted from the
226 primary medical record it is not subject to recall bias. Limitations of this analysis include the
227 small percentage of non-white subjects in this geographic region, the potential for confounding
228 due to the observational nature of the study, as well as the data currently available being biased
229 toward those vaccinated later in gestation and skewed toward the population in the United
230 States healthcare workforce. Finally, only two COVID-19 infections occurred in the vaccinated
231 group early in pregnancy, so they may be a group who had lower baseline exposure compared
232 to the unvaccinated group.

233 Our findings should give clinicians confidence that COVID-19 vaccination during pregnancy is
234 effective in preventing maternal SARS-CoV-2 infection, and that no pattern of adverse maternal
235 or neonatal outcomes is evident during pregnancy, adding to the growing body of evidence
236 supporting the safety of COVID vaccines in pregnant women. Additional studies will be needed
237 to examine differences in rare adverse birth outcomes, as well as outcomes following
238 vaccination during early pregnancy. Outreach to under-represented populations of pregnant
239 patients should be a focus of future education and vaccination efforts.

240

241

242

243 **References**

244

- 245 1. BADEN LR, EL SAHLY HM, ESSINK B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
246 New England Journal of Medicine 2021;384:403-16.
- 247 2. POLACK FP, THOMAS SJ, KITCHIN N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
248 Vaccine. New England Journal of Medicine 2020;383:2603-15.
- 249 3. ADHIKARI EH, SPONG CY. COVID-19 Vaccination in Pregnant and Lactating Women. JAMA
250 2021;325:1039-40.
- 251 4. Vaccinating Pregnant and Lactating Patients Against COVID-19 *Practice Advisory: American*
252 *College of Obstetrics and Gynecology*, 2021.
- 253 5. VILLAR J, ARIFF S, GUNIER RB, et al. Maternal and Neonatal Morbidity and Mortality Among
254 Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort
255 Study. JAMA pediatrics 2021.
- 256 6. ADHIKARI EH, MORENO W, ZOFKIE AC, et al. Pregnancy Outcomes Among Women With and Without
257 Severe Acute Respiratory Syndrome Coronavirus 2 Infection. JAMA network open
258 2020;3:e2029256-e56.
- 259 7. LOKKEN EM, HUEBNER EM, TAYLOR GG, et al. Disease severity, pregnancy outcomes, and maternal
260 deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection
261 in Washington State. American Journal of Obstetrics and Gynecology 2021.
- 262 8. COLLIER A-RY, MCMAHAN K, YU J, et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant
263 and Lactating Women. JAMA 2021.
- 264 9. SHIMABUKURO TT, KIM SY, MYERS TR, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in
265 Pregnant Persons. New England Journal of Medicine 2021:NEJMoa2104983-NEJMoa83.

266
267

268 **Table 1. Demographics of the study population**

COVID Vaccine				
	No (N=1862)	Yes (N=140)	Total (N=2002)	P-value
Maternal Age at Delivery				<.0001 ¹
N	1862	140	2002	
Mean (SD)	30.0 (5.23)	31.8 (3.72)	30.1 (5.16)	
Median	30	32	30	
Range	16.0, 48.0	20.0, 40.0	16.0, 48.0	
Race, n (%)				0.1299 ⁴
Asian	89 (4.8%)	6 (4.3%)	95 (4.7%)	
Black or African American	99 (5.3%)	3 (2.1%)	102 (5.1%)	
Not Disclosed	146 (7.8%)	3 (2.1%)	149 (7.4%)	
White	1528 (82.1%)	128 (91.4%)	1656 (82.7%)	
Ethnicity, n (%)				0.0323 ⁴
Hispanic or Latino	173 (9.3%)	5 (3.6%)	178 (8.9%)	
Not Hispanic or Latino	1651 (88.7%)	132 (94.3%)	1783 (89.1%)	
Unknown	38 (2.0%)	3 (2.1%)	41 (2.0%)	
Education, yrs., n (%)				<.0001 ⁴
<12	70 (4.7%)	0 (0.0%)	70 (4.3%)	
12-16	1218 (81.9%)	70 (53.4%)	1288 (79.6%)	
>16	199 (13.4%)	61 (46.6%)	260 (16.1%)	
Missing	375	9	384	
Current Smoker, n (%)	196 (10.5%)	0 (0.0%)	196 (9.8%)	<.0001 ²
Illicit Drug Use, n (%)	56 (3.0%)	0 (0.0%)	56 (2.8%)	0.0301 ³
Gravidity, n (%)				0.0065 ⁴
1	546 (29.3%)	56 (40.0%)	602 (30.1%)	
2	519 (27.9%)	34 (24.3%)	553 (27.6%)	
3	350 (18.8%)	29 (20.7%)	379 (18.9%)	
4+	447 (24.0%)	21 (15.0%)	468 (23.4%)	
Pre-Pregnancy BMI, n (%)				0.0036 ⁴
<25	573 (39.6%)	70 (56.5%)	643 (41.0%)	
25-30	409 (28.3%)	21 (16.9%)	430 (27.4%)	
30-35	226 (15.6%)	15 (12.1%)	241 (15.4%)	

35-40	139 (9.6%)	14 (11.3%)	153 (9.7%)	
40+	99 (6.8%)	4 (3.2%)	103 (6.6%)	
Missing	416	16	432	
Pre-Gestational Diabetes, n (%)	11 (0.6%)	2 (1.4%)	13 (0.6%)	0.2292 ³
Pre-Gestational Hypertension, n (%)	64 (3.4%)	6 (4.3%)	70 (3.5%)	0.6295 ³
Asthma, n (%)	206 (11.1%)	15 (10.7%)	221 (11.0%)	0.8989 ²
Infertility Treatment, n (%)	14 (0.8%)	6 (4.3%)	20 (1.0%)	0.0018 ³
Multiple Gestation, n (%)				0.6826 ³
Singleton	1840 (98.8%)	138 (98.6%)	1978 (98.8%)	
Twins	22 (1.2%)	2 (1.4%)	24 (1.2%)	
GBS Test Result, n (%)				0.7453 ⁴
Negative	1283 (68.9%)	94 (67.1%)	1377 (68.8%)	
Not Tested	274 (14.7%)	20 (14.3%)	294 (14.7%)	
Positive	305 (16.4%)	26 (18.6%)	331 (16.5%)	
¹ T-test p-value; ² Chi-Square p-value; ³ Fisher's Exact Test p-value; ⁴ Wilcoxon Rank Sum p-value				

269

270

271 **Table 2. Maternal and delivery outcomes after vaccination during pregnancy**

272

	COVID Vaccine		Total (N=2002)	P-value
	No (N=1862)	Yes (N=140)		
Covid-19 Infection During Pregnancy, n (%)				0.0004 ⁴
None	1652 (88.7%)	138 (98.6%)	1790 (89.4%)	
Trimester 1	26 (1.4%)	0 (0.0%)	26 (1.3%)	
Trimester 2	84 (4.5%)	2 (1.4%)*	86 (4.3%)	
Trimester 3	100 (5.4%)	0 (0.0%)	100 (5.0%)	
Adverse Outcomes Index (AOI), n (%)	91 (4.9%)	7 (5.0%)	98 (4.9%)	0.9524 ¹
AOI Excluding Laceration, n (%)	55 (3.0%)	5 (3.6%)	60 (3.0%)	0.6071 ³
Hypoxic, Ischemic Encephalopathy, n (%)	1 (0.1%)	0 (0.0%)	1 (0.0%)	1.00 ³
Uterine Rupture, AOI, n (%)	1 (0.1%)	0 (0.0%)	1 (0.0%)	1.00 ³
Unplanned ICU Admission, n (%)	2 (0.1%)	1 (0.7%)	3 (0.1%)	0.1956 ³
Birth Trauma, n (%)	11 (0.6%)	0 (0.0%)	11 (0.5%)	1.00 ³
Return to OR, n (%)	6 (0.3%)	1 (0.7%)	7 (0.3%)	0.3985 ³
NICU admit > 2500g, n (%)	11 (0.6%)	1 (0.7%)	12 (0.6%)	0.5821 ³
5 Minute Apgar <7, n (%)	38 (2.0%)	3 (2.1%)	41 (2.0%)	0.7617 ³
Hemorrhage with transfusion, n (%)	5 (0.3%)	1 (0.7%)	6 (0.3%)	0.3531 ³
3rd or 4th degree laceration, n (%)	37 (2.0%)	2 (1.4%)	39 (1.9%)	1.00 ³
Mode of Delivery, n (%)				0.6518 ¹
Spontaneous Vaginal	1238 (66.5%)	89 (63.6%)	1327 (66.3%)	
Operative Vaginal	69 (3.7%)	7 (5.0%)	76 (3.8%)	
Cesarean	555 (29.8%)	44 (31.4%)	599 (29.9%)	

Gestational Age Delivery, n (%)				0.7028 ¹
37+	1703 (91.5%)	127 (90.7%)	1830 (91.4%)	
32-36 6/7	134 (7.2%)	10 (7.1%)	144 (7.2%)	
24-31 6/7	21 (1.1%)	2 (1.4%)	23 (1.1%)	
<24	4 (0.2%)	1 (0.7%)	5 (0.2%)	
Length of Stay				0.2744 ²
Mean (SD)	1.8 (0.76)	1.9 (0.87)	1.8 (0.76)	
Median	2	2	2	
Range	0.0, 8.0	1.0, 7.0	0.0, 8.0	
Quantitative Blood Loss > 1000mL, n (%)	57 (3.1%)	6 (4.3%)	63 (3.1%)	0.4452 ³
Transfusion, n (%)	241 (12.9%)	25 (17.9%)	266 (13.3%)	0.1198 ³
Thromboembolism, n (%)	2 (0.1%)	0 (0%)	2 (0.1%)	1.00 ³
Stroke, n (%)	1 (0.1%)	0 (0.0%)	1 (0.0%)	1.00 ³
Eclampsia / Pre-Eclampsia (+/- 72 hours of Delivery), n (%)	23 (1.2%)	1 (0.7%)	24 (1.2%)	1.00 ³
Gestational Hypertension, n (%)	225 (12.1%)	19 (13.6%)	244 (12.2%)	0.6038 ¹
Low Birth Weight (<2500g), n (%)	121 (6.5%)	11 (7.9%)	132 (6.6%)	0.5321 ¹
Very Low Birth Weight (<1500g), n (%)	21 (1.1%)	3 (2.1%)	24 (1.2%)	0.2332 ³
StillBirth, n (%)	6 (0.3%)	0 (0.0%)	6 (0.3%)	1.00 ³
*Infections occurred prior to first dose of vaccine				
¹ Chi-Square test; ² Kruskal-Wallis test; ³ Fisher's Exact test				